Up next

Autoplay

Dr. Jonathan Trent on FDA Approval of Trabectedin for Soft Tissue Sarcomas

14 Views • 07/18/23
Share
Embed
administrator
administrator
Subscribers
0

Jonathan C. Trent, MD, professor of Medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay